Varamir
Desk
News
Calendar
Pricing
Saved
Search
tickers or companies
⌘K
Start free
· no card
Sign in
IBIO compared with LLY: revenue, margins and what each company keeps, and the suppliers and customers both name
IBIO
iBio, Inc.
Change
Mkt cap
Revenue
Revenue
LLY
ELI Lilly & Co
Change
Mkt cap
Revenue
Revenue
vs
Compare
IBIO
iBio, Inc.
vs
LLY
ELI Lilly & Co
Price
Mkt cap
Revenue
Revenue
Change
Change
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Save comparison
Copy link
Revenue flow
Desk
News
Calendar
Saved
Search
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Price
Supply-chain overlap
Revenue flow
IBIO: latest quarter is a loss; flow not drawable.
Method
›
Supply-chain overlap
direct ties · both sides
Sources
›
direct ties · both sides
Only IBIO
16
TWST
Twist Bioscience
supplier
—
AstralBio
unlisted
supplier
—
Chardan
unlisted
supplier
—
Lonza Sales
unlisted
supplier
12 more · IBIO chain
›
Shared
0
No shared counterparties.
Only LLY
29
MCK
McKesson
customer
CAH
Cardinal Health
customer
VEEV
Veeva Systems
supplier
UTHR
United Therapeutics
customer
Role chip = supplier or customer
—
= no ticker (unlisted)
Source: SEC EDGAR
25 more · LLY chain
›
Price
rebased to 0%
1D
1W
1M
3M
YTD
1Y
5Y
1D
1W
1M
3M
YTD
1Y
5Y
IBIO, solid
LLY, dashed
IBIO
iBio, Inc.
Change
0.72
▼
−10.01%
Mkt cap
$51.4M
Revenue
$100,000
Q1 FY26
Revenue
—
LLY
ELI Lilly & Co
Change
1,388.07
▼
−2.11%
Regular session
Nov 5 '26
Mkt cap
$1.3T
Revenue
$24.4B
Q3 FY26
Revenue
$65.2B
FY25
vs
Compare
Regular session
Nov 5 '26
IBIO
iBio, Inc.
vs
LLY
ELI Lilly & Co
0.72
▼
−10.01%
Price
1,388.07
▼
−2.11%
$51.4M
Mkt cap
$1.3T
Q1 FY26
$100,000
Revenue
$24.4B
Q3 FY26
—
Revenue
$65.2B
FY25
Change
Change
IBIO
0.72
▼
−10.01%
vs
LLY
1,388.07
▼
−2.11%
Regular session
Nov 5 '26